Discontinued — last reported Q2 '22
PG&E Short-Term Borrowings decreased by 37.4% to $1.68B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.9%, from $1.52B to $1.68B. Over 5 years (FY 2020 to FY 2025), Short-Term Borrowings shows a downward trend with a -5.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
High levels may indicate a reliance on short-term credit markets for operational cash flow, which can increase liquidity risk.
Short-term borrowings consist of debt obligations that are due within one year, excluding the current portion of long-te...
Varies by industry; pharmaceutical firms often maintain access to short-term credit for operational flexibility.
short_term_borrowings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.12B | $2.47B | $2.18B | $1.85B | $2.13B | $1.80B | $2.06B | $1.30B | $125.00M | $580.00M | $3.97B | $2.82B | $4.97B | $2.02B | $1.52B | $1.52B | $1.52B | $1.03B | $2.68B | $1.68B |
| QoQ Change | — | +16.6% | -11.6% | -15.1% | +15.1% | -15.9% | +14.5% | -37.0% | -90.3% | +364.0% | +584.7% | -29.0% | +76.4% | -59.3% | -24.7% | +0.1% | +0.0% | -32.7% | +161.0% | -37.4% |
| YoY Change | — | — | — | — | +0.7% | -27.3% | -5.9% | -30.2% | -94.1% | -67.7% | +93.2% | +117.6% | >999% | +248.6% | -61.6% | -45.9% | -69.3% | -49.3% | +75.6% | +9.9% |